Skip to main content
SpringerLink
Log in

Hepatologie (I)

  • Conference paper
Handbuch Gastroenterologie 2010

Part of the book series: Handbuch Update-Seminar ((UPDATESEMINAR))

  • 1100 Accesses

Zusamenfassung

Einige empfehlenswerte Übersichtsartikel zum Management von Patienten mit akutem Leberversagen auf der Intensivstation, der Koagulopathie sowie zum Stellenwert der therapeutischen Hypothermie wurden 2009 publiziert (1,2,3,4).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

14.10 Literatur

  1. Kramer DJ, Canabal JM, Arasi LC: Application of intensive care medicine principles in the management of the acute liver failure patient. Liver Transpl 2008;14S2:S85–9.

    Article  Google Scholar 

  2. Trotter JF: Practical management of acute liver failure in the Intensive Care Unit. Curr Opin Crit Care 2009;15:163–7.

    Article  PubMed  Google Scholar 

  3. De Gasperi A, Corti A, Mazza E, Prosperi M, Amici O, Bettinelli L: Acute liver failure: managing coagulopathy and the bleeding diathesis. Transplant Proc 2009;41:1256–9.

    Article  PubMed  Google Scholar 

  4. Stravitz RT, Larsen FS: Therapeutic hypothermia for acute liver failure. Crit Care Med 2009; 37: S258–64.

    Article  PubMed  Google Scholar 

  5. Lee WM, Hynan LS, Rossaro L, Fontana RJ, Stravitz RT, Larson AM, Davern TJ 2nd, Murray NG, McCashland T, Reisch JS, Robuck PR; Acute Liver Failure Study Group.: Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure.. Gastroenterology 2009;137:856–64.

    Google Scholar 

  6. James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Davern TJ, Lee WM: Pharmacokinetics of acetaminophen-protein adducts in adults with acetaminophen overdose and acute liver failure. Drug Metab Dispos 2009;37:1779–84.

    Article  CAS  PubMed  Google Scholar 

  7. Acharya SK, Bhatia V, Sreenivas V, Khanal S, Panda SK: Efficacy of L-ornithine L-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study. Gastroenterology 2009;136:2159–68.

    Article  CAS  PubMed  Google Scholar 

  8. Jalan R, Lee WM: Treatment of hyperammonemia in liver failure: a tale of two enzymes. Gastroenterology 2009;136:2048–51.

    Article  CAS  PubMed  Google Scholar 

  9. Ytrebø LM, Kristiansen RG, Maehre H, Fuskevåg OM, Kalstad T, Revhaug A, Cobos MJ, Jalan R, Rose CF: L-ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure. Hepatology. 2009;50:165–74.

    Article  PubMed  Google Scholar 

  10. Davies NA, Wright G, Ytrebo LM, Stadibauer V, Fuskevåg OM, Zwingmann C, Davies DC, Habtesion A, Hodges SJ, Jalan R: L-ornithine and phenylacetate synergistically produce sustained reduction in ammonia and brain water in cirrhotic rats. Hepatology. 2009;50:155–64.

    Article  CAS  PubMed  Google Scholar 

  11. Yamagishi Y, Saito H, Ebinuma H, Kikuchi M, Ojiro K, Kanamori H, Tada S, Horie Y, Kato S, Hibi T: A new prognostic formula for adult acute liver failure using computer tomography-derived hepatic volumetric analysis. J Gastroenterol. 2009;44:615–23.

    Article  PubMed  Google Scholar 

  12. Perkins JD: Another formula to determine the prognosis of patients with acute liver failure. Liver Transpl 2009;15:986–91.

    Article  PubMed  Google Scholar 

  13. Korman JD. Montefiore Medical Center, Bronx, NY, USA: Screening for Wilson disease in acute liver failure: a comparison of currently available diagnostic tests. Hepatology 2008; 48:1167–74.

    Article  CAS  PubMed  Google Scholar 

  14. Dowling D: Screening for Wilson’s disease in acute liver failure: a comparison of currently available diagnostic tests. Hepatology 2009;50:329.

    Article  PubMed  Google Scholar 

  15. Daniels D, Grytdal S, Wasley A; Centers for Disease Control and Prevention (CDC): Surveillance for acute viral hepatitis — United States, 2007. MMWR Surveill Summ 2009;58: 1–27.

    PubMed  Google Scholar 

  16. Aggarwal R, Naik S: Epidemiology of hepatitis E: current status. J Gastroenterol Hepatol 2009;24:1484–93.

    Article  PubMed  Google Scholar 

  17. Lewis HC, Wichmann O, Duizer E: Transmission routes and risk factors for autochthonous hepatitis E virus infection in Europe: a systematic review. Epidemiol Infect 2010;138:145–66.

    Article  CAS  PubMed  Google Scholar 

  18. FitzSimons D, Hendrickx G, Vorsters A, Van Damme P: Hepatitis A and E: update on prevention and epidemiology. Vaccine 2010;28:583–8.

    Article  PubMed  Google Scholar 

  19. Teo CG: Much meat, much malady: changing perceptions of the epidemiology of hepatitis E. Vaccine 2010;28:583–8.

    Article  Google Scholar 

  20. Kuniholm MH, Purcell RH, McQuillan GM, Engle RE, Wasley A, Nelson KE: Epidemiology of hepatitis E virus in the United States: results from the Third National Health and Nutrition Examination Survey, 1988-1994. J Infect Dis 2009;200:48–56.

    Google Scholar 

  21. Adlhoch C, Wolf A, Meisel H, Kaiser M, Ellerbrok H, Pauli G: High HEV presence in four different wild boar populations in East and West Germany. Vet Microbiol 2009; 139:270–8.

    Article  PubMed  Google Scholar 

  22. Khuroo MS, Kamili S, Khuroo MS: Clinical course and duration of viremia in vertically transmitted hepatitis E virus (HEV) infection in babies born to HEV-infected mothers. J Viral Hepat 2009;16:519–23.

    Article  CAS  PubMed  Google Scholar 

  23. le Coutre P, Meisel H, Hofmann J, Röcken C, Vuong GL, Neuburger S, Hemmati PG, Dörken B, Arnold R: Reactivation of hepatitis E infection in a patient with acute lymphoblastic leukaemia after allogeneic stem cell transplantation. Gut. 2009;58:699–702.

    Article  PubMed  Google Scholar 

  24. EASL clinical practice guidelines: Management of chronic hepatitis B. J Hepatol 2009;51:227–42.

    Google Scholar 

  25. Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, Kern ER, McHugh JA, Petersen GM, Rein MF, Strader DB, Trotter HT: National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology 2009;49: S4–S12.

    Article  PubMed  Google Scholar 

  26. Kim WR, Terrault NA, Pedersen RA, Therneau TM, Edwards E, Hindman AA, Brosgart CL: Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology 2009;137:1680–6.

    Article  PubMed  Google Scholar 

  27. Toy M, Veldhuijzen IK, de Man RA, Richardus JH, Schalm SW: Potential impact of long-term nucleoside therapy on the mortality and morbidity of active chronic hepatitis B. Hepatology 2009;50:743–51.

    Article  CAS  PubMed  Google Scholar 

  28. Yu JW, Sun LJ, Zhao YH, Kang P, Li SC: The Study of Efficacy of Lamivudine in Patients with Severe Acute Hepatitis B. Dig Dis Sci 2009; in press.

    Google Scholar 

  29. Pei SN, Chen CH, Lee CM, Wang MC, Ma MC, Hu TH, Kuo CY: Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 2009;21; in press.

    Google Scholar 

  30. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, Hui EP, Lei Kl, Mok TS, Chan PK: Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009;27:605–11.

    Article  CAS  PubMed  Google Scholar 

  31. Thompson SC, Levy MT, Wiseman E: Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust 2009;191:357.

    PubMed  Google Scholar 

  32. Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM, Zhang SL, Qiao FY, Campbell F, Chang CN, Gardner S, Atkins M: Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebocontrolled study. J Viral Hepat 2009;16:94–103.

    Article  PubMed  Google Scholar 

  33. Marcellin P, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Jin R, Gurel S, Lu ZM, Wu J, Popescu M, Hadziyannis S; Peginterferon aIfa-2a in HBeAg-negative Chronic Hepatitis B Study Group: Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009;136:2169–2179.

    Article  CAS  PubMed  Google Scholar 

  34. Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, Dauvergne A, Asselah T, Boyer N, Bedossa P, Valla D, Vidaud M, Nicolas-Chanoine MH, Marcellin P: Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009;49:1151–7.

    Article  CAS  PubMed  Google Scholar 

  35. Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Luo K, Wang Y, Hadziyannis S, Wolf E, Mc Cloud P, Batrla R, Marcellin P: Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009;49:1141–50.

    Article  CAS  PubMed  Google Scholar 

  36. Buster EH, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW, Janssen HL: Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009;137:2002–9.

    Article  CAS  PubMed  Google Scholar 

  37. van Bömmel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, Erhardt A, Hüppe D, Stein K, Trojan J, Sarrazin C, Böcher WO, Spengler U, Wasmuth HE, Reinders JG, Möller B, Rhode P, Feucht HH, Wiedenmann B, Berg T: Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology. 2010;51:73–80.

    PubMed  Google Scholar 

  38. Lange CM, Bojunga J, Hofmann WP, Wunder K, Mihm U, Zeuzem S, Sarrazin C: Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009;50:2001–6.

    Article  CAS  PubMed  Google Scholar 

  39. Ha NB, Ha NB, Garcia RT, Trinh HN, Vu AA, Nguyen HA, Nguyen KK, Levitt BS, Nguyen MH: Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology 2009;50:727–34.

    Article  CAS  PubMed  Google Scholar 

  40. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J, Wilber RB, Colonno RJ: Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009;49:1503–1.

    Article  CAS  PubMed  Google Scholar 

  41. Fung J, Lai CL, Tanaka Y, Mizokami M, Yuen J, Wong DK, Yuen MF: The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion. Am J Gastroenterol 2009;104:1940–6.

    Article  CAS  PubMed  Google Scholar 

  42. Liu CJ, Chuang WL, Lee CM, Yu ML, Lu SN, Wu SS, Liao LY, Chen CL, Kuo HT, Chao YC, Tung SY, Yang SS, Kao JH, Liu CH, Su WW, Lin CL, Jeng YM, Chen PJ, Chen DS: Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 2009;136:496–504.

    Article  CAS  PubMed  Google Scholar 

  43. Rizzetto M: Hepatitis D: thirty years after. J Hepatol 2009;50:1043–50.

    Article  CAS  PubMed  Google Scholar 

  44. Romeo R, Del Ninno E, Rumi M, Russo A, Sangiovanni A, de Franchis R, Ronchi G, Colombo M: A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology 2009;136:1629–38.

    Article  PubMed  Google Scholar 

  45. Deuffic-Burban S, Babany G, Lonjon-Domanec I, Deltenre P, Canva-Delcambre V, Dharancy S, Louvet A, Roudot-Thoraval F, Mathurin P: Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France. Hepatology 2009;50:1351–9.

    Article  CAS  PubMed  Google Scholar 

  46. Mangia A, Minerva N, Bacca D, Cozzolongo R, Agostinacchio E, Sogari F, Scotto G, Vinelli F, Ricci GL, Romano M, Carretta V, Petruzzellis D, Andriulli A: Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection. Hepatology 2009; 49:358–63.

    Article  CAS  PubMed  Google Scholar 

  47. Berg T, Weich V, Teuber G, Klinker H, Möller B, Rasenack J, Hinrichsen H, Gerlach T, Spengler U, Buggisch P, Balk H, Zankel M, Neumann K, Sarrazin C, Zeuzem S: Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. Hepatology 2009;50:369–77.

    Article  CAS  PubMed  Google Scholar 

  48. Moreno C, Deltenre P, Pawlotsky JM, Henrion J, Adler M, Mathurin P: Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: A meta-analysis. J Hepatol 2010;52:25–31.

    Article  CAS  PubMed  Google Scholar 

  49. Ferenci P, Laferl H, Scherzer TM, Maieron A, Hofer H, Stauber R, Gschwantler M, Brunner H, Wenisch C, Bischof M, Strasser M, Datz C, Vogel W, Löschenberger K, Steindl-Munda P; Austrian Hepatitis Study Group: Peginterferon Alfa-2a/Ribavirin for 48 or 72 Weeks in Hepatitis C Types 1 and 4 Patients With Slow Virologic Response. Gastroenterology 2010. in press

    Google Scholar 

  50. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS; IDEAL Study Team: Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580–93.

    Article  CAS  PubMed  Google Scholar 

  51. Ascione A, Luca MD, Tartaglione MT, Lampasi F, Di Costanzo GG, Lanza AG, Picciotto FP, Marsilia GM, Fontanella L, Leandro G: Peginterferon alfa-2a Plus Ribavirin Is More Effective Than Peginterferon alfa-2b Plus Ribavirin for Treating Chronic Hepatitis C Virus Infection. Gastroenterology 2009; in press.

    Google Scholar 

  52. Falasca K, Ucciferri C, Mancino P, Gorgoretti V, Pizzigallo E, Vecchiet J: Use of Epoetin Beta during combination therapy of infection with Hepatitis C Virus with ribavirin improves a sustained viral response. J Med. Virol 2010;82:49–56.

    Article  CAS  PubMed  Google Scholar 

  53. Shiffman ML, Morishima C, Dienstag JL, Lindsay KL, Hoefs JC, Lee WM, Wright EC, Naishadham D, Everson GT, Lok AS, Di Bisceglie AM, Bonkovsky HL, Ghany MG; HALT-C Trial Group: Effect of HCV RNA suppression during peginterferon Alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. Gastroenterology 2009;137:1986–94.

    Article  CAS  PubMed  Google Scholar 

  54. Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, Moreno-Otero R, Carrilho F, Schmidt W, Berg T, McGarrity T, Heathcote EJ, Gonçales F, Diago M, Craxi A, Silva M, Bedossa P, Mukhopadhyay P, Griffel L, Burroughs M, Brass C, Albrecht J; Epic Study Group: Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009;136:1618–28.

    Article  CAS  PubMed  Google Scholar 

  55. Jensen DM, Marcellin P, Freilich B, Andreone P, Di Bisceglie A, Brandão-Mello CE, Reddy KR, Craxi A, Martin AO, Teuber G, Messinger D, Thommes JA, Tietz A: Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann intern Med. 2009;150:528–40.

    PubMed  Google Scholar 

  56. Ahmed Belkacam A, Ahnou N, Barbotte L, Wychowski C, Pallier C, Brillet R, Pohl RT, Pawlotsky JM: Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA — Dependent RNA Polymerase. Gastroenterology 2009. (in press).

    Google Scholar 

  57. Biermer M, Berg T: Rapid suppression of hepatitis C viremia induced by intravenous silibinin plus ribavirin. Gastroenterology 2009;137:390–1.

    Article  PubMed  Google Scholar 

  58. Sulkowski: MS, Zeuzem S, Lawitz E, Grigorescu M, Tice A, Rustgi VK, Rodriguez-Torres M, Lurie Y, Cianciara J, Bacon BR, Bain VG, Kryczka W, Pukstenis E, Subramanian GM, McHutchison JG: Efficacy and safety of albinterferon alfa-2B in combination with ribavirin in treatment naïve patients with chronic Hepatitis C genotype 1. Hepatology 2009;50:333A.

    Google Scholar 

  59. Benhamou Y, Nelson DR, Chuang WL, Lawitz E, Flisiak R, Raseneck J, Kryczka W, Lee CM, Rodriguez-Torres M, Bain VG, Schiff ER, Cho M, Janczewska-Kazek E, Peng CY, Pulkstenis E, Subramanian GM, McHutschison JG: Efficacy and safety results of albinterferon alfa-2b in combination with ribavirin in treatment naïve subjects with chronic hepatitis C genotype 2 or 3. Hepatology 2009;50:1026A.

    Article  Google Scholar 

  60. Burton JR Jr, Everson GT: HCV NS5B polymerase inhibitors. Clin Liver Dis. 2009;13:453–65.

    Article  PubMed  Google Scholar 

  61. Thompson AJ, McHutchison JG: Antiviral resistance and specifically targeted therapy for HCV (STAT-C). J Viral Hepat 2009;16:377–87.

    Article  CAS  PubMed  Google Scholar 

  62. Thompson AJ, McHutchison JG: Review article: investigational agents for chronic hepatitis C. Aliment Pharmacol Ther 2009;29:689–705.

    Article  CAS  PubMed  Google Scholar 

  63. Thompson A, Patel K, Tillman H, McHutchison JG: Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges. J Hepatol 2009;50:184–94.

    Article  CAS  PubMed  Google Scholar 

  64. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS; IDEAL Study Team: Peginterferon alfa-2b or aIfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580–93.

    Article  CAS  PubMed  Google Scholar 

  65. Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourlière M, Gharakhanian S, Bengtsson L, McNair L, George S, Kieffer T, Kwong A, Kauffman RS, Alam J, Pawlotsky JM, Zeuzem S; PROVE2 Study Team: Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360:1839–50.

    Article  PubMed  Google Scholar 

  66. Rossignol JF, Eifert A, El-Gohary Y, Keeffe EB: Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology 2009;136:856–62.

    Article  CAS  PubMed  Google Scholar 

  67. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M: Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461:798–801.

    Article  CAS  PubMed  Google Scholar 

  68. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J: IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41:1100–4.

    Article  CAS  PubMed  Google Scholar 

  69. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M: Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105–9.

    Article  CAS  PubMed  Google Scholar 

  70. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399–401.

    Article  CAS  PubMed  Google Scholar 

  71. Cohen SM, Ahn J: Review article: the diagnosis and management of alcoholic hepatitis. Aliment Pharmacol Ther 2009;30:3–13.

    Article  CAS  PubMed  Google Scholar 

  72. O’Shea RS, Dasarathy S, McCullough AJ; Practice Guideline: Alcoholic liver disease. Hepatology. 2010 Jan;51(1):307–28

    Google Scholar 

  73. Sharma P, Kumar A, Sharma BC, Sarin SK: Infliximab monotherapy for severe alcoholic hepatitis and predictors of survival: an open label trial. J Hepatol 2009;50:584–91.

    Article  CAS  PubMed  Google Scholar 

  74. De BK, Gangopadhyay S, Dutta D, Baksi SD, Pani A, Ghosh P: Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World J Gastroenterol. 2009;15:1613–9.

    Article  CAS  PubMed  Google Scholar 

  75. Louvet A, Wartel F, Castel H, Dharancy S, Hollebecque A, Canva-Delcambre V, Deltenre P, Mathurin P: Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology 2009; 137:541–8.

    Article  CAS  PubMed  Google Scholar 

  76. Tian C, Stokowski RP, Kershenobich D, Ballinger DG, Hinds DA: Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet 2010;42:21–3.

    Article  CAS  PubMed  Google Scholar 

  77. Hirschfield GM, Liu X, Xu C, Lu Y, Xie G, Lu Y, Gu X, Walker EJ, Jing K, Juran BD, Mason AL, Myers RP, Peltekian KM, Ghent CN, Coltescu C, Atkinson EJ, Heathcote EJ, Lazaridis KN, Arnos Cl, Siminovitch KA: Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med 2009;360:2544–55.

    Article  CAS  PubMed  Google Scholar 

  78. McNally RJ, Ducker S, James OF: Are transient environmental agents involved in the cause of primary biliary cirrhosis?. Evidence from space-time clustering analysis. Hepatology 2009; 50:1169–74.

    Article  PubMed  Google Scholar 

  79. Kuiper EM, Hansen BE, de Vries RA, den Ouden-Muller JW, van Ditzhuijsen TJ, Haagsma EB, Houben MH, Witteman BJ, van Erpecum KJ, van Buuren HR; Dutch PBC Study Group: Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009;136: 1281–7.

    Article  CAS  PubMed  Google Scholar 

  80. Milkiewicz P, Buwaneswaran H, Coltescu C, Shums Z, Norman GL, Heathcote EJ: Value of autoantibody analysis in the differential diagnosis of chronic cholestatic liver disease. Clin Gastroenterol Hepatol 2009;7:1355–60.

    Article  PubMed  Google Scholar 

  81. Feuchtinger M, Christ S, Preuss B, Dengjel J, Duman S, Stevanovic S, Klein R: Detection of novel non-M2-related antimitochondrial antibodies in patients with anti-M2 negative primary biliary cirrhosis. Gut 2009;58:983–9.

    Article  CAS  PubMed  Google Scholar 

  82. Yeoman AD, Westbrook RH, Al-Chalabi T, Carey I, Heaton ND, Portmann BC, Heneghan MA: Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease. Hepatology 2009;50:538–4.

    Article  PubMed  Google Scholar 

  83. Aw MM, Dhawan A, Samyn M, Bargiota A, Mieli-Vergani G: Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. J Hepatol 2009;51:156–60.

    Article  CAS  PubMed  Google Scholar 

  84. Wolf DC, Bojito L, Facciuto M, Lebovics E: Mycophenolate mofetil for autoimmune hepatitis: a single practice experience. Dig Dis Sci 2009;54:2519–22.

    Article  CAS  PubMed  Google Scholar 

  85. Webster GJ, Pereira SP, Chapman RW: Autoimmune pancreatitis/lgG4-associated cholangitis and primary sclerosing cholangitis-overlapping or separate diseases? J Hepatol 2009;51:398–402.

    Article  CAS  PubMed  Google Scholar 

  86. Alderlieste YA, van den Elzen BD, Rauws EA, Beuers U: Immunoglobulin G4-associated cholangitis: one variant of immunoglobulin G4-related systemic disease. Digestion 2009;79: 220–8.

    Article  CAS  PubMed  Google Scholar 

  87. Ghazale A, Chari ST, Zhang L, Smyrk TC, Takahashi N, Levy MJ, Topazian MD, Clain JE, Pearson RK, Petersen BT, Vege SS, Lindor K, Farnell MB: Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 2008;134:706–15.

    PubMed  Google Scholar 

  88. Chung H, Watanabe T, Kudo M, Maenishi O, Wakatsuki Y, Chiba T: Identification and characterization of lgG4-associated autoimmune hepatitis. Liver Int 2009; in press.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gastroenterologe & Rheumatologie Sektion Hepatologie, Universitätsklinikum Leipzig AöR Klinik und Poliklinik für, Liebigstr 20, 04103, Leipzig, Deutschland

    Prof. Dr. Thomas Berg

Authors
  1. Prof. Dr. Thomas Berg
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Kiinik für Aiigemein- und Viszeraichirurgie, Dr. Horst Schmidt Kiiniken GmbH, Ludwig-Erhard-Straße 100, 65199, Wiesbaden

    Christian Eli

  2. Medizinische Klinik, Israelitisches Krankenhaus, Orchideenstieg 14, 22297, Hamburg

    Peter Layer

  3. II. Medizinische Kiinik, Kiinikum Aschaffenburg, Am Hasenkopf 1, 63739, Aschaffenburg

    Wolfgang Fischbach

  4. Chirurgisches Zentrum Viszeral-, Gefäß- und Endokrine Chirurgie, HELlOS Kiinikum Wuppertal, Heusnerstraße 40, 42283, Wuppertai

    Hubert Zirngibl

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Medizin Verlag Heidelberg

About this paper

Cite this paper

Berg, T. (2010). Hepatologie (I). In: Eli, C., Layer, P., Fischbach, W., Zirngibl, H. (eds) Handbuch Gastroenterologie 2010. Handbuch Update-Seminar. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-11635-3_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-11635-3_14

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-11634-6

  • Online ISBN: 978-3-642-11635-3

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation